Outcomes following general anaesthesia in children with hypertrophic cardiomyopathy by Norrish, G et al.
 
 Outcomes following general anaesthesia in children with hypertrophic cardiomyopathy 
 
Dr Gabrielle Norrisha,b, BMBCh, Dr Natalie Forshawc, MBBS, Dr Colleen Woo,c MBBS, Dr 
Mary Claire Avanisc, MBBS, Ms Ella Fielda, BSc, Dr Elena Cervia, MBBS, Dr Akane Iguchic, 
MBBS, Dr Juan Pablo Kaskia,b, MBBS 
 
Affiliations: 
aCentre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, UK; and 
bInstitute of Cardiovascular Sciences University College London, UK, and cDepartment of 
Anaesthesia, Great Ormond Street Hospital, London 
 
 
Address for correspondence:  
Dr Juan Pablo Kaski 
Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, WC1N 
3JH  
Email: j.kaski@ucl.ac.uk  
Tel:020 7405 9200 ext 5418 
Fax: 020 7762 6727 
 
 
Word count: 2500 
 
 
Financial Disclosure: The authors have no financial relationships relevant to this article to disclose 
 
Funding source: This work was supported by the British Heart Foundation 
 


























Children with hypertrophic cardiomyopathy (HCM) have historically been considered to be high 
risk candidates for general anaesthesia (GA), but there is currently a paucity of evidence 
regarding the safety of anaesthesia and peri-operative outcomes in this population. 
Methods 
Clinical features and outcomes of all paediatric patients (<18 years) with HCM undergoing 
GA between 2000-2016 were reviewed.  
Results 
86 patients (median 12.4 years (IQR 6.5, 14.9)) underwent 164 separate GA procedures. 
Aetiology included non-syndromic disease (n=44, 56%), malformation syndromes (n= 22, 
26%), inborn error of metabolism (n=10, 12%) and neuromuscular disease (n=4,5%). At the 
time of GA, mean maximal wall thickness (MWT) on echocardiography was 19mm (SD+/- 
8mm), 23 patients (14%) had severe left ventricular hypertrophy (MWT >30mm) and 35 
patients (21%) had a hemodynamically significant left ventricular outflow tract (LVOT) 
gradient (>50mmHg). The majority (n=143, 87%) had no peri-operative complications. 20 
patients (12%) had minor peri-operative complications: bradycardia (n=4), hypotension 
(n=15) or transient ST segment changes (n=1). One patient (0.6% of GA procedures) 
experienced a cardiac arrest during anaesthetic induction with death occurring 3 days later. 
Clinical parameters (including age, MWT, LVOT gradient, systolic and diastolic dysfunction) 
were not associated with an increased risk of complications  
Conclusions 
This is the largest published series to date of paediatric HCM patients undergoing GA, which 
demonstrates that, in an expert centre, patients can be anaesthetized with a relatively low peri-
anaesthetic mortality (0.6%) and prevalence of minor complications (12%). Future studies are 
















Hypertrophic cardiomyopathy (HCM) is the second most common cause of cardiomyopathy 
during childhood, with an estimated annual incidence of 0.24-0.47 per 100,000 1-3. The majority 
of disease is caused by mutations in the cardiac sarcomere protein genes4, however aetiology is 
heterogeneous and also includes malformation syndromes, inborn errors of metabolism and 
neuromuscular diseases. Phenotypic expression is highly variable, but can include severe left 
ventricular hypertrophy (LVH), dynamic left ventricular outflow tract obstruction (LVOTO), 
impaired diastolic function and a predisposition to ventricular arrhythmias. The dynamic nature 
of LVOTO in HCM, caused by systolic anterior motion of the mitral valve (SAM), means that 
gradients can be exacerbated by changes in heart rate, heart rhythm, preload and/or afterload, 
with resulting hemodynamic instability. Although global systolic function is typically preserved, 
patients with HCM commonly have reduced LV compliance and diastolic dysfunction and are 
reliant on pre-load to maintain cardiac output. Finally, the hypertrophied left ventricle has an 
increased myocardial oxygen demand, resulting in a higher risk of coronary blood flow 
insufficiency and myocardial ischemia. Given these characteristics, children with HCM have 
historically been viewed as high risk general anaesthesia (GA) candidates. Peri-operative 
outcomes of adult HCM patients have been reported in the literature, although often with 
conflicting findings. However, there is currently a lack of evidence regarding the optimal peri-
operative management and safety of GA in the paediatric HCM population.  The aim of this 
study was to determine the safety and outcomes of paediatric patients with HCM undergoing GA 
in a specialised centre.  
 
Patients and Methods 
 
Patients: 
Clinical cardiac and anaesthetic data from children with HCM undergoing GA under the age of 
18 years at Great Ormond Street Hospital between 2000 and 2016 were reviewed retrospectively. 
Patients were identified from anaesthetic records and a clinical database. All patients fulfilled 
conventional diagnostic criteria for HCM (maximal left ventricle wall thickness greater than two 
standard deviations (SD) above the predicted body surface area (BSA)-corrected mean in the 
absence of abnormal loading conditions)5,6 . Patients were not included in this series if they 
underwent anaesthesia for cardiac surgery requiring cardiopulmonary bypass; had a ventricular 
assist device in situ (VAD); or were post heart transplantation. When patients had more than one 
anaesthetic, data were collected from all episodes, with descriptive demographic data obtained 




Anonymized, non-invasive clinical information from the time of anaesthetic was collected 
including: demographics; aetiology; pedigree; symptoms; and two-dimensional (2D) 
transthoracic echocardiography (TTE) data. Aetiology was classified as non-syndromic in the 
absence of a diagnosis of a RASopathy syndrome (Noonan or other malformation syndrome), 
neuromuscular disease (including Friedreich’s ataxia) or inborn error of metabolism.  
Echocardiographic measurements were made according to current guidelines7,8. Specifically, 
maximum LV wall thickness (MLVWT) was defined as the greatest thickness in any single 
segment at end diastole as measured by 2D echocardiography. Peri-operative information 
collected included: details of procedure performed; anaesthetic management; intraoperative 
pharmacological and physiological data; post-operative care; and complications occurring intra-
operatively or within 24 hours of anaesthesia. Hypotension, tachycardia and bradycardia were 
defined as values more than 30% above or below patient’s own baseline or those outside age-
specific normal values.  
Major complications were defined a priori as peri-operative mortality, myocardial infarction 
(MI), stroke or congestive cardiac failure (CCF). Minor complications were defined a priori as a 
transient disturbance in blood pressure, heart rate or arrhythmias requiring treatment, or the need 
for an unplanned intensive care admission.  
 
Definitions: 
Severe LVH was defined as MLVWT  30mm in any myocardial segment6. Impaired left 
ventricular systolic function was defined as LV fractional shortening < 25%, as measured in 
parasternal long or short axis (2D or M Mode) or ejection fraction <50% using Simpson’s 
biplane volumetric method7. LV diastolic dysfunction was assessed to be present if two out of 
the four variables used to assess diastolic function were out of normal range for age and body 
surface area (annular E’ velocity, average E/E’ ratio, LA volume and peak TR velocity)8. LVOT 
obstruction was defined as an instantaneous peak Doppler LVOT pressure gradient ≥ 30mmHg 
at rest. A hemodynamically significant gradient was considered to be an instantaneous peak 
Doppler gradient ≥ 50mmHg9. Non-sustained ventricular tachycardia (NSVT) was defined as 
three or more consecutive ventricular beats at a rate of greater than 120 beats/min with a duration 
of less than 30 seconds on ambulatory electrocardiograph (ECG) recordings5. 
 
Ethical approval: 
This study was approved by Great Ormond Street Hospital/ University College London Institute 
of Child Health Research and Development Office.  
 
Statistical analysis: 
All statistical analyses were performed using STATA (Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP).  BSA was calculated from height and weight10. Normally 
distributed continuous variables are described as mean +/- standard deviation with two group 
comparisons conducted using Student t test. Skewed data are described as median (interquartile 
range, IQR) with two group comparisons performed using Wilcoxon rank sum. To determine the 
association between relevant predictors and a composite outcome of primary or secondary 
outcomes, univariate analysis was performed using Chi Squared test or Fishers exact test. To 
account for multiple comparisons, the Bonferroni correction was applied, accepting a p value 





Eighty-six eligible patients with HCM under the age of 18 underwent 164 separate general 
anaesthetics between 2000 and 2016. 78 patients (90%) underwent more than one anaesthetic. 48 
patients (56%) had non-syndromic HCM, of whom 22 (46%) had undergone genetic testing. 
Pathogenic mutations in sarcomeric protein genes were identified in 15 patients (68% of those 
tested).  22 patients (26%) had a RASopathy syndrome, 10 (12%) an inborn error of metabolism 
and 4 (5%) a neuromuscular disorder. Data on baseline clinical characteristics and co-morbidities 
are shown in table 1. 4 patients had a previous history of an out of hospital arrest. 13 patients 
(15%) had a history of NSVT on ambulatory ECG monitoring 
 
Clinical phenotype at time of anaesthesia: 
Mean MLVWT at the time of anaesthesia was 19mm (SD 8.3mm, range 4-49mm). The 
distribution of hypertrophy was asymmetric in 106 patients (68%), concentric in 47 (30%), and 
biventricular in 3 (2%). 23 patients (14%) had severe LVH. Of 47 patients (31%) with LVOTO 
at rest, 35 patients (21%) had a hemodynamically significant gradient (>50mmHg) and one 
patient had severe outflow tract obstruction (>90mmHg). 87 patients (53%) had 
echocardiographic evidence of impaired LV diastolic performance and 10 patients (6%) had 
impaired LV systolic function. 24 patients (15%) had an ICD in situ at the time of anaesthesia. 
105 patients (64%) were on medical therapy for symptom control. 46 patients (28%) were on 
more than one medication (table 1).    
 
Indication for general anaesthetic: 
150 (91%) general anaesthetics were for elective procedures. The indication for anaesthetic is 
shown in table 2.  
 
Peri-operative anaesthetic management: 
Details on peri-operative anaesthetic management are summarized in table 3. The lead 
anaesthetic provider was a consultant cardiac anaesthetist in 75 (46%), consultant non-cardiac 
anaesthetist in 76 (46%) and a senior anaesthetic trainee doctor in 13 (8%). 100 patients (61%) 
had an intravenous induction; phenylephrine was used empirically at induction in 8 patients (5%) 
with no subsequent recorded hypotension. In 153 patients (93%), anaesthesia was maintained 
with volatile agents. All patients had intra-operative non-invasive cardio-respiratory monitoring, 
47 patients (29%) had invasive arterial blood pressure monitoring and 14 (9%) central venous 
pressure monitoring. 
 
Peri-operative complications : 
Of a total of 164 anaesthetics in children with HCM, 143 (87%) had no peri-operative 
complications. 20 patients (12%) had minor peri-operative complications:  15 patients had intra-
operative hypotension requiring treatment; 4 had intra-operative bradycardia requiring treatment; 
and 1 patient had transient ST segment changes not requiring treatment. 1 patient (0.6%) had a 
major complication, with cardiac arrest occurring after induction of general anaesthesia requiring 
extracorporeal-cardiopulmonary resuscitation (ECPR) and death occurring three days later. This 
patient had familial HCM with a severe phenotype: asymmetric hypertrophy (MWT 20mm); 
LVOTO at rest (55 mmHg) managed with medical therapy (atenolol and disopyramide) and 
short AV delay dual chamber pacing; and evidence of left ventricular diastolic impairment with 
left atrial dilatation. A primary prevention ICD had previously been implanted following 
syncopal events and the detection of NSVT on ambulatory ECG monitoring. No clinical 
parameters were associated with an increased risk of reaching the composite outcome of any 
post-operative complication (Table 4).  
 
Post-operative course: 
Post-operative recovery took place on a cardiology ward for 91 patients (55%), including 10 
(6%) who had undergone non-cardiac procedures. 17 patients (10%) were managed post-
operatively on intensive care, including 2 patients who had an unplanned admission: one 
following a failed extubation, and one post cardiac arrest requiring extracorporeal membrane 
oxygenator (ECMO) support (as described above). Length of stay ranged from 0 to 21 days 
(median 1 day); 104 procedures (63%) were completed as day-case admissions and did not 




To our knowledge, this is the largest study of peri-anaesthetic outcomes in children with HCM to 
date. The results demonstrate that, in a heterogeneous cohort of HCM patients having a GA at an 
experienced centre, the majority of patients (n=143, 87%) had no peri-operative complications 
and two thirds of procedures were performed as day-cases requiring no overnight stay. Minor 
peri-operative complications were seen in 12% of patients but there was one peri-operative 
mortality (0.6%) in an adolescent with severe HCM.  
 
 
Comparison with previous literature  
 
To date, no large cohort studies describing the safety of general anaesthesia in paediatric HCM 
have been published and most of the literature consists of single case reports. The largest 
published paediatric series reported the outcome of 129 patients with different cardiomyopathies 
undergoing anaesthesia in a single centre, of whom 50 had HCM11. No deaths were reported 
among the HCM patients, but the study was limited by a lack of detailed clinical description of 
patients. The scarcity of paediatric data mean that expected outcomes for these patients are often 
extrapolated from adult studies, the findings of which have been conflicting. Early reports 
described a high frequency of peri-anaesthetic adverse events of up to 40% in adult HCM 
patients12. However, more recent studies describing larger populations of patients have reported a 
lower risk of cardiovascular adverse events, although the risk is nonetheless increased compared 
to controls13. In the study by Dhillon and colleagues, 20% of HCM patients reached a composite 
end point of death, myocardial infarction (MI), stroke or congestive cardiac failure (CCF); this 
was mostly driven by decompensated CCF and the absolute number of deaths, MI, or stroke was 
low and not significantly different to what was seen in an age-matched control group14. The 
reported proportion of adult HCM patients dying in the peri-operative period in the literature 
ranges from 4 to 6.7%13,14, which is higher than that seen in our cohort. This difference in 
mortality is unlikely to be explained by a milder disease phenotype. Whilst the adult studies had 
a higher proportion of patients with LVOTO (53% vs 30.5%) and diastolic dysfunction (93% vs 
55%), the absolute maximal wall thickness and proportion of patients with a previous ventricular 
arrhythmia were not significantly different. The difference in mortality could be explained by the 
higher proportion of patients in the adult cohorts with additional co-morbidities such as 
hypertension, diabetes, and atrial fibrillation which are known to independently increase the risk 
of a GA.  
 
 
Identifying patients at high risk of adverse events  
 
Although the prevalence of adverse events is lower than historically reported, the ability to 
identify patients at higher risk would help guide clinical management. However, no data 
currently exist to guide peri-anaesthetic risk stratification in paediatric HCM. In an adult cohort, 
the presence of LVOT obstruction at rest (gradient >30mmHg), a high American Society of 
Anesthesiologists (ASA) risk score 15or intra-operative hypotension were associated with a 
higher risk of having an adverse event14. Our ability to systematically investigate individual risk 
factors for an adverse peri-operative outcome in this study was limited by low numbers of 
adverse events in this cohort. No single parameter, including MLVWT, LVOTO and diastolic 
impairment, was found to be associated with a peri-anaesthetic complication. However, it is 
likely that the combination of certain phenotypic features may confer a higher risk. Certainly, the 
single patient who experienced a major complication had severe disease with significant left 
ventricular hypertrophy, LVOT obstruction, diastolic impairment and a history of ventricular 
arrhythmias. While larger studies are required to identify clinical features’ that may confer a 
higher anaesthetic risk, in clinical practice, it is essential that each individual patient is 
systematically assessed prior to a GA.  
 
 
Importance of expert centres 
 
Childhood HCM is a rare disease and compared to adult HCM populations, the disease in 
childhood is more heterogeneous in terms of aetiology, symptoms and outcomes.3,16,17 The 
cohort of childhood HCM patients reported here is representative of other cohorts described in 
population-based or registry studies1,2,18. It includes patients with phenotypically severe disease 
as defined by severe left ventricular hypertrophy, left ventricular outflow tract obstruction, 
diastolic impairment and previous ventricular arrhythmias. The results are therefore likely to be 
generalizable to the wider paediatric HCM population. However, this cohort is derived from a 
single centre with medical, surgical and anaesthetic expertise in managing patients with this 
heterogeneous disease. To allow for individualised peri-operative planning, a multi-disciplinary 
team meeting (including the paediatric HCM specialists and anaesthetic consultants) is held in 
advance of any procedure requiring a general anaesthetic. The low prevalence of adverse 
outcomes may not be replicable in non-specialist centres. It is important to note that early reports 
from adult cohorts, which reported a higher prevalence of adverse events, were indeed derived 
from non-specialist centres. This includes the largest cohort of HCM patients undergoing GA to 
date (n=227), which identified patients from the US National Hospital Discharge Survey13,  a 
fifth of whom underwent GA procedures in community based hospitals which may lack the 
expertise to manage these patients. This study reported an increased risk of death (odds ratio 
1.61) or MI in adults with HCM compared to age matched controls, a finding that has not been 
replicated in subsequent cohort studies from specialist centres. The low prevalence of adverse 




This study is limited by problems inherent to retrospective studies, including missing or 
incomplete data. Additionally, although this is the largest cohort of paediatric HCM patients 
undergoing a GA reported in the literature, the interpretation of the prevalence of complications 
is limited by the absence of age matched controls. Previous studies have reported 30-day 
mortality of 1.1/10,000 (95% CI 0.4-2.6) in a non-selective cohort of children undergoing GA at 
a tertiary paediatric hospital19. In contrast, in the largest study to date assessing outcomes 
following non-cardiac surgery in children with congenital heart disease (CHD), higher post-
operative mortality 3.9-8.2% rates were described in patients with moderate (defined as repaired 
CHD with residual hemodynamic abnormality) and severe (including patients with ventricular 
dysfunction requiring medication or uncorrected cyanotic heart disease) CHD compared to 
controls (1.7-1.2%)20. This suggests that, although children with HCM have a higher incidence 
of major complications following anaesthesia compared to the general population, the risk may 
be lower than in children with other cardiac disease. This series did not include patients 
undergoing cardiac surgery requiring CPB as the interpretation of the a priori defined 
complications (in particular disturbances in blood pressure, heart rate or arrhythmias) would not 
be possible once CPB was established. Future studies investigating the outcome of children with 
HCM undergoing GA for procedures requiring CPB would be useful.  
 
Conclusion: 
This study reports the largest published series of patients with paediatric HCM undergoing 
general anaesthesia and demonstrates a relatively low peri-anaesthetic mortality (0.6%) and 
prevalence of minor complications (12%). The findings suggest that, in an expert centre, children 
with HCM can be anesthetised with a low risk of adverse events. Future studies are required to 




What is already known on this topic 
 Children with Hypertrophic cardiomyopathy (HCM) have historically been considered to 
be high risk candidates for general anaesthesia (GA), but there is currently a paucity of 
evidence regarding the safety of anaesthesia and peri-operative outcomes in this 
population. 
 
What this study adds 
 In an expert centre, paediatric patients with HCM can be anaesthetized with a low peri-
anaesthetic mortality (0.6%) and low prevalence of minor complications (12%). Future 
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Data expressed as number (%). Total number of patients is 86 unless otherwise stated. ENT = Ears, 








 Number (%) 
Male gender 50 (58) 
Age, yrs (median (range)) 12.4 (0-18.4) 
Weight, Kg (median (range)) 38.6 (2-101) 
Cardiac medications  
 Beta-blockers 91 (55) 
 Disopyramide 38 (23) 
 Calcium channel blockers 16 (10) 
 Amiodarone 10 (6) 
Comorbidities (n)  
ENT OSA 3 
Orthopaedic Scoliosis 4 
 Polyarthralgia 1 
Respiratory Asthma 4 
Congenital cardiac disease VSD 1 
 Aortic stenosis 1 
Neurology Epilepsy 1 
 Autistic spectrum disorder 3 
 Developmental delay 
(acquired/congenital) 
3 
 hydrocephalus 1 
Metabolic Diabetes mellitus 2 





Table 2: Indication for general anaesthetic 
 
  Number (%) 
Cardiac  87 (53) 
 Implantation/threshold 
testing of ICD 
56 
 Diagnostic cardiac 
catheterisation 
7 
 Interventional cardiac 
catheterisation 
1 
 EPS 9 
 Pacemaker implantation 8 




General surgical   11 (7) 
 Gastrointestinal 7 
 Biopsy/excision 4 
Radiology  26 (16) 
 Diagnostic 9 
 Interventional 17 
Orthopaedic  12 (8) 
Ears, nose and throat  8 (5) 
Dental  8 (5) 
Plastics  2 (1) 
Neurosurgery  2 (1) 
Urology  7 (4) 
Respiratory  1 (<1) 
Data expressed as number (%). Total number of GA procedures is 164. ICD = Implantable 











Anaesthetic detail Number (%) 
Lead anaesthetic 
provider 
Consultant - Cardiac 75 (46) 
Consultant - Non-Cardiac 76 (46) 
Senior trainee doctor 13 (8) 
Anxiolytic premedication used  34 (21) 
Mode of induction Gaseous 60 (37) 
 Sevofluarane 60 
Intravenous (IV) 100 (61) 
 Propofol & opioid 40 
 Etomidate & opioid 33 
 Ketamine & opioid  5 
 Propofol only 15 
 Other 7 
Mixed (IV + gas) 4 (2) 
Airway Management Endotracheal intubation 142 (87) 
Laryngeal Mask Airway 19 (12) 
Other 3 (2) 
Maintenance Volatile 153 (93) 
TIVA 9 (5) 
Not specified 2 (1) 
Vasopressor agent  
(n=17, 10%) 
Phenylephrine  14 (9) 
Noradrenaline 3 (1) 
 



















No Complication  P value  
Age, yrs (median 
(IQR)) 
10.74 (0.23 - 16.6) 10.4 (0.01 - 18.43) >0.999 
Weight, Kg (median 
(range)) 




10% (n=2/21) 8% (n=11/140) >0.999+ 
ASH distribution, 
n% 
65% (n=13/20) 67% (n=91/136) >0.999 
Systolic dysfunction, 
n% 
20% (n=4/20) 4% (n=6/136) 0.064 
Diastolic dysfunction, 
n% 
89% (n=16/18) 74% (n=71/96) >0.999 
LVOT gradient, n% 
>50mmHG  
24% (n=5/21) 17% (n=23/136) >0.999+ 
MLVWT > 30mm, 
n% 
15% (n=3/20) 16% (n=20/129) >0.999+ 
Data expressed as % (n=proportion of patients with available data). Comparisons performed using 
Chi-Squared test unless otherwise stated. + Fishers Exact test. LVOT = left ventricular outflow 
tract, MLVWT = maximal left ventricular wall thickness, ASH = Asymmetric septal hypertrophy  
 
